Lower, More Frequent Cisplatin Dosing Substantially Reduces Hearing Loss in Head and Neck Cancer Without Compromising Short‑Term Survival
Highlight
- In a multicenter retrospective cohort of 564 patients with head and neck squamous cell carcinoma (HNSCC), weekly low‑dose cisplatin was associated with markedly lower rates and severity of hearing loss than standard high‑dose cisplatin given every 3 weeks.
- Absolute reductions were large: any hearing loss by CTCAE criteria fell from 69% to 39% and CTCAE grade ≥2 hearing loss from 50% to 18% with weekly dosing.
- Two‑year overall and disease‑free survival were similar between groups, supporting consideration of weekly cisplatin where hearing preservation is a priority.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.